SLC5A2 and type 1 diabetes mellitus: SGLT-2 inhibitors have been approved for T2DM in many countries, and their efficacy and safety have been widely recognized.[7] However, the efficacy and safety of SOTA adjuvant therapy for T1DM remain controversial.